Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase 1/2 1

Status

Active not recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 3Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Melanoma 3Prostatic Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1

Interventions

pembrolizumab 519Specimen Handling 382Carboplatin 374Magnetic Resonance Spectroscopy 337Cisplatin 328Nivolumab 309Cyclophosphamide 296Radiotherapy 256Paclitaxel 256Gemcitabine 235Biopsy 234Bevacizumab 213Dexamethasone 169durvalumab 166Oxaliplatin 162Rituximab 158Capecitabine 157Fluorouracil 148venetoclax 147Docetaxel 146Etoposide 141atezolizumab 140Drug Therapy 140Doxorubicin 134Ipilimumab 130Prednisone 120Lenalidomide 119Radiosurgery 118Leucovorin 112fludarabine 108

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Introns × 1 year × Clear all
NCT03899987 2026-05-05

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Roswell Park Cancer Institute

Phase 2 Active not recruiting
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT01708941 2026-04-30

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
88 enrolled 14 charts
Dermatologic

Melanoma

NCT02737046 2026-03-10

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

University of Miami

Phase 2 Completed
15 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Roswell Park Cancer Institute

Phase 2 Terminated
1 enrolled
Dermatologic

Melanoma

NCT00539591 2025-12-23

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
29 enrolled 28 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡